News GW files cannabis-based epilepsy drug in EU and US After Sativex disappointment, Epidiolex could transform GW's fortunes.
News GW prepares for 2018 US launch of epilepsy drug But Zynerba's cannabis epilepsy drug fails in phase 2.
News GW close to filing cannabis-based epilepsy drug Epidiolex could become a blockbuster if approved in all uses.
News GW could be next big pharma takeover target UK firm has hired bankers to deal with approaches - press reports.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
